<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00332930</url>
  </required_header>
  <id_info>
    <org_study_id>VIR-NCHR-02</org_study_id>
    <nct_id>NCT00332930</nct_id>
  </id_info>
  <brief_title>ITV Extension Study</brief_title>
  <official_title>An Extension Study to Protocol VIR-NCHR-01 to Assess the Antiretrovirological Properties of a Therapeutic HIV Vaccine Candidate Based on Recombinant Fowlpox Virus (rFPV) (ITV Extension Study)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kirby Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>The University of New South Wales</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Virax Pty. Ltd,</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Kirby Institute</source>
  <brief_summary>
    <textblock>
      The objective of this phase I/II therapeutic human immunodeficiency virus (HIV) vaccine&#xD;
      candidate study is to provide proof of concept for a HIV antigen delivery system in terms of&#xD;
      safety, virological effects and selected immune responses in HIV infected individuals after&#xD;
      cessation of antiretroviral combination therapy (ART).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A multi-centre, double-blind, placebo-controlled, 20-week parallel group extension study to&#xD;
      the VIR-NCHR-01 protocol (ITV study). The purpose of the extension study is to assess the&#xD;
      safety and virological effects of a therapeutic HIV vaccine strategy in HIV-1 infected adults&#xD;
      currently enrolled in the ITV study after cessation of antiretroviral therapy. Two active&#xD;
      candidate vaccines will be studied in this trial: The active treatment arms will receive&#xD;
      recombinant fowlpoxvirus (rFPV) expressing HIV gag-pol antigens or HIV gag-pol antigens and&#xD;
      interferon-gamma (IFN-y) in diluent. Vaccines will be delivered by intramuscular injection.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2002</start_date>
  <completion_date>September 2003</completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time weighted area under the curve change from plasma HIV-RNA VL at baseline (day 0) until reintroduction of antiretroviral therapy</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Log plasma HIV-RNA load after cessation of combination ART (post-vaccination viral load (VL) set-point)</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Kinetics and rate of VL recrudescence and median time to re-initiation of ART</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CD8+ T-cell responses to HIV antigens assessed through:</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Enzyme linked immunospot (ELISPOT) assay of IFN-y secreting cells</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Intracellular Cytokine Cytometry (ICC) for IFN-y and CD69</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Human Leucocyte Antigen (HLA) class I/ I matched tetramer analyses for HIV epitope specific CD8+/CD4+ T -cells</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CD4+/CD8+ T-cell count changes</measure>
  </secondary_outcome>
  <enrollment>35</enrollment>
  <condition>HIV</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>recombinant fowlpoxvirus (rFPV) expressing HIV gag-pol antigens</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>HIV gag-pol antigens and interferon-gamma (IFN-y)</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  HIV-1 infected individuals eligible and still fulfilling the criteria for the&#xD;
             VIR-NCHR-01 protocol (ITV study)&#xD;
&#xD;
          -  Received all 3 immunisations&#xD;
&#xD;
          -  Remained in follow-up for at least 52 weeks&#xD;
&#xD;
          -  Continued to take combination antiretroviral therapy with no evidence of treatment&#xD;
             failure at the time entering the roll-over phase&#xD;
&#xD;
          -  Written informed consent obtained&#xD;
&#xD;
        Criteria for Withdrawal of Study Participants&#xD;
&#xD;
          -  Incidental or progression of disease which, in the opinion of the principal&#xD;
             investigator, should preclude further study participation&#xD;
&#xD;
          -  If the study participant required cytotoxic or immunosuppressive chemo- or radiation&#xD;
             therapy&#xD;
&#xD;
          -  If the study participant required any medications that when combined with the study&#xD;
             vaccination, would in the opinion of the principal investigator, jeopardise the&#xD;
             validity of the individual's continued participation&#xD;
&#xD;
          -  Administration of prohibited alternative therapy&#xD;
&#xD;
          -  Study participant non-compliance&#xD;
&#xD;
          -  All study participants are required to adhere to the protocol evaluation schedule.&#xD;
             Failure to adhere with this schedule without having first provided justification may&#xD;
             result in the participant being withdrawn from the study&#xD;
&#xD;
          -  At the request of the study participant or principal investigator without prejudice to&#xD;
             future health care&#xD;
&#xD;
          -  In the opinion of the investigator, if it is not in the patient's best interests to&#xD;
             continue the study&#xD;
&#xD;
          -  At the request of the National Centre in HIV Epidemiology and Clinical Research&#xD;
             (NCHECR) with reasonable cause&#xD;
&#xD;
          -  At the advice of the Data Safety Monitoring Board (DSMB)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David A Cooper, AO DSc MD FRACP FRCPA FRCP</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Centre in HIV Epidemiology and Clinical Research.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>407 Doctors</name>
      <address>
        <city>Sydney</city>
        <state>New South Wales</state>
        <zip>2010</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ground Zero Medical Practice</name>
      <address>
        <city>Sydney</city>
        <state>New South Wales</state>
        <zip>2010</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Holdsworth House Medical Practice</name>
      <address>
        <city>Sydney</city>
        <state>New South Wales</state>
        <zip>2010</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St Vincents Hospital</name>
      <address>
        <city>Sydney</city>
        <state>New South Wales</state>
        <zip>2010</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Alfred Hospital</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <zip>3004</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Carlton Clinic</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <zip>3053</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
  </location_countries>
  <verification_date>June 2006</verification_date>
  <study_first_submitted>June 1, 2006</study_first_submitted>
  <study_first_submitted_qc>June 1, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 2, 2006</study_first_posted>
  <last_update_submitted>February 26, 2007</last_update_submitted>
  <last_update_submitted_qc>February 26, 2007</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 27, 2007</last_update_posted>
  <keyword>HIV</keyword>
  <keyword>Therapeutic vaccine</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Interferons</mesh_term>
    <mesh_term>Interferon-gamma</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

